What's Happening?
Forge Biologics, a gene therapy contract development and manufacturing organization, is set to deliver seven presentations at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting.
The presentations will highlight advancements in their FUEL™ AAV manufacturing platform, which aims to improve scalability and support the growing number of gene therapy programs advancing toward commercialization. Forge's presentations will cover process innovations, late-phase manufacturing frameworks, and advancements in purification technologies. The company is focused on enabling more doses per batch and improving manufacturing efficiency to meet the increasing demand for gene therapies.
Why It's Important?
As the gene therapy field matures, the need for efficient and scalable manufacturing solutions becomes critical. Forge Biologics' innovations in AAV manufacturing could significantly impact the industry by reducing production costs and increasing the availability of gene therapies. This is particularly important as more gene therapy programs move into late-stage development and commercialization. By improving manufacturing processes, Forge is helping to accelerate the delivery of life-changing therapies to patients with genetic diseases, potentially transforming treatment options and outcomes.
